

Financial news for CYTK dated on 2020-05-27: Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS

Financial news for CYTK dated on 2020-05-19: The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces \$1.34B Common Stock Offering

Financial news for CYTK dated on 2020-05-13: The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter

Financial news for CYTK dated on 2020-05-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CYTK dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for CYTK dated on 2020-05-12: Morgan Stanley Maintains Overweight on Cytokinetics, Raises Price Target to \$29

Financial news for CYTK dated on 2020-05-12: 78 Biggest Movers From Yesterday

Financial news for CYTK dated on 2020-05-11: Mid-Afternoon Market Update: NASDAQ Rises Over 100 Points; Amneal Pharmaceuticals Shares Surge On Upbeat Results

Financial news for CYTK dated on 2020-05-11: 54 Stocks Moving In Monday's Mid-Day Session

Financial news for CYTK dated on 2020-05-11: Stocks That Hit 52-Week Highs On Monday

Financial news for CYTK dated on 2020-05-08: FDA Grants Amgen And Cytokinetics Fast Track Designation For Omecamtiv Mecarbil In Heart Failure

Financial news for CYTK dated on 2020-05-06: Cytokinetics Q1 EPS \$(0.660) Misses \$(0.500) Estimate

Financial news for CYTK dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for CYTK dated on 2020-05-05: Benzinga's Top Upgrades, Downgrades For May 5, 2020

Financial news for CYTK dated on 2020-05-05: Mizuho Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target to \$31

Financial news for CYTK dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for CYTK dated on 2020-04-23: Cytokinetics And Astellas Pharma Inc. Entered Two Agreements, Which Amend And Restate Co's Research, Development Commercialization Collaboration

Financial news for CYTK dated on 2020-04-17: 10 Biggest Price Target Changes For Friday

Financial news for CYTK dated on 2020-04-17: Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Raises Price Target to \$23

Financial news for CYTK dated on 2020-04-14: Cytokinetics Says Believes It Is On Track To Achieve Its Key Strategic Objectives For 2020

Financial news for CYTK dated on 2020-04-09: Benzinga's Top Upgrades, Downgrades For April 9, 2020

Financial news for CYTK dated on 2020-04-09: 10 Biggest Price Target Changes For Thursday

Financial news for CYTK dated on 2020-04-09: Cytokinetics shares are trading higher after Morgan Stanley upgraded the company's stock from Equal-Weight to Overweight and raised its price target from \$14 to \$25.

Financial news for CYTK dated on 2020-04-09: Morgan Stanley Upgrades Cytokinetics to Overweight, Raises Price Target to \$25

Financial news for CYTK dated on 2020-03-30: Cytokinetics Q1 EPS \$(0.04) Down From \$0.15 YoY

Financial news for CYTK dated on 2020-03-26: Shares of several healthcare companies are trading higher following Senate passage of a \$2 trillion economic stimulus package, which has lifted stocks across sectors.

Financial news for CYTK dated on 2020-03-04: Cytokinetics Granted European Orphan Designation For Reldesemtiv For The Treatment Of Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2020-03-03: Cytokinetics Sees FY20 Cash Revenues \$18M-\$22M

Financial news for CYTK dated on 2020-03-03: Cytokinetics Q4 EPS \$(0.52) Misses \$(0.44) Estimate, Sales \$5.2M Miss \$7.19M Estimate

Financial news for CYTK dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for CYTK dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for CYTK dated on 2020-02-26: Amgen, Cytokinetics, Servier Report Continuation Of GALACTIC-HF Following Interim Analysis

Financial news for CYTK dated on 2020-02-19: The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA

Financial news for CYTK dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for CYTK dated on 2020-02-13: Stocks That Hit 52-Week Highs On Thursday

Financial news for CYTK dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for CYTK dated on 2020-02-12: Stocks That Hit 52-Week Highs On Wednesday

Financial news for CYTK dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for CYTK dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for CYTK dated on 2020-02-06: Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Financial news for CYTK dated on 2020-01-06: Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274

Financial news for CYTK dated on 2020-01-02: Cytokinetics Director Henderson Buys 6,000 @\$8.57

Financial news for CYTK dated on 2019-12-18: Cytokinetics Granted FDA Orphan Drug Designation For Reldesemtiv For Treatment Of Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2019-12-16: 58 Biggest Movers From Friday

Financial news for CYTK dated on 2019-12-05: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

Financial news for CYTK dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for CYTK dated on 2019-11-20: 77 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-11-11: Cytokinetics Highlights Will Present Added Results From COSMIC-HF Phase 2 Trial At American Heart Association Scientific Sessions 2019

Financial news for CYTK dated on 2019-11-08: 94 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-11-07: 75 Stocks Moving In Thursday's Mid-Day Session

Financial news for CYTK dated on 2019-10-31: Cytokinetics Q3 EPS \$(0.5) Down From \$(0.4) YoY

Financial news for CYTK dated on 2019-10-04: Cytokinetics Highlights Presentation Of Added Analyses From FORTITUDE-ALS At NEALS Meeting

Financial news for CYTK dated on 2019-09-27: 50 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-09-26: Cytokinetics To Present Additional Results From FORTITUDE-ALS At 18th Annual NEALS Meeting Oct.13

Financial news for CYTK dated on 2019-09-16: Cytokinetics Highlights Data From Phase 1 Study Of CK-3773274 At HFSA Meeting

Financial news for CYTK dated on 2019-09-10: 84 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for CYTK dated on 2019-09-06: Stocks That Hit 52-Week Highs On Friday

Financial news for CYTK dated on 2019-09-06: 10 Biggest Price Target Changes For Friday

Financial news for CYTK dated on 2019-09-06: Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Raises Price Target to \$20

Financial news for CYTK dated on 2019-08-09: A List Of Stocks Reaching New 52-Week Highs

Financial news for CYTK dated on 2019-08-08: Cytokinetics Q2 EPS \$(0.56) Misses \$(0.5) Estimate, Sales \$7.137M Beat \$6.99M Estimate; Results From Phase 1 Study Of Ck-274 To Be Presented At Hfssa In September 2019; Phase 2 Clinical Trial Expected To Begin In Q4

Financial news for CYTK dated on 2019-08-08: Stocks That Set New 52-Week Highs Thursday

Financial news for CYTK dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for CYTK dated on 2019-08-07: Stocks That Managed To Breach 52-Week Highs Wednesday Morning

Financial news for CYTK dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for CYTK dated on 2019-07-31: Stocks That Managed to Breach 52-Week Highs Wednesday Morning

Financial news for CYTK dated on 2019-07-31: Cytokinetics Reports Preclinical Data For CK-3773274 Presented At American Heart Association's Basic Cardiovascular Sciences Scientific Sessions

Financial news for CYTK dated on 2019-07-26: Companies That Achieved 52-Week Highs Friday

Financial news for CYTK dated on 2019-07-24: Cytokinetics Highlights Publication Of Preclinical Data Showing Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics

Financial news for CYTK dated on 2019-07-23: Cytokinetics Reports Was Granted European Orphan Designation For Reldesemtiv For Treatment Of Spinal Muscular Atrophy

Financial news for CYTK dated on 2019-07-22: Cytokinetics Highlights Presentation Of Preclinical Data Related To CK-3773274 At American Heart Association's Basic Cardiovascular Sciences Scientific Sessions

Financial news for CYTK dated on 2019-07-15: Cytokinetics Announces Completion Of Enrollment In GALACTIC-HF, Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

Financial news for CYTK dated on 2019-06-28: Cytokinetics Reports Preclinical Data For Reldesemtiv Was Presented At 2019 Annual Cure SMA Conference

Financial news for CYTK dated on 2019-06-24: Cytokinetics Reports Will Present Preclinical Data For Reldesemtiv At SMA Conference Jun. 28, 29

Financial news for CYTK dated on 2019-06-18: 60 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-05-28: 50 Biggest Movers From Friday

Financial news for CYTK dated on 2019-05-24: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for CYTK dated on 2019-05-10: Cytokinetics shares are trading higher after the company reported better-than-expected Q1 sales results.

Financial news for CYTK dated on 2019-05-09: Cytokinetics Q1 EPS \$(0.54) Misses \$(0.47) Estimate, Sales \$8.464M Beat \$6.86M Estimate

Financial news for CYTK dated on 2019-05-06: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Mon., May 6, 2019

Financial news for CYTK dated on 2019-05-06: 26 Stocks Moving In Monday's Pre-Market Session

Financial news for CYTK dated on 2019-05-05: Cytokinetics Announces FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS Did Not Meet Statistical Significance for Primary Efficacy Analysis

Financial news for CYTK dated on 2019-05-04: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Financial news for CYTK dated on 2019-04-29: Cytokinetics Option Alert: May 17 \$9 Calls at the Ask: 1406 @ \$1.101 vs 1461 OI; Earnings 5/7 After Close [est] Ref=\$9.29

Financial news for CYTK dated on 2019-04-01: Cytokinetics Option Alert: May 17 \$10 Calls at the Ask: 1200 @ \$0.35 vs 72 OI; Earnings 4/25 After Close [est] Ref=\$8.05

Financial news for CYTK dated on 2019-03-22: 60 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for CYTK dated on 2019-03-21: 52 Biggest Movers From Yesterday

Financial news for CYTK dated on 2019-03-20: 41 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CYTK dated on 2019-03-20: Cytokinetics shares are trading higher after the Data Monitoring Committee for the company's GALACTIC-HF recommended Cytokinetics' phase 3 trial continue without changes.

Financial news for CYTK dated on 2019-03-20: Amgen, Cytokinetics, Servier Report Continuation Of GALACTIC-HF Following Planned Interim Analysis

Financial news for CYTK dated on 2019-03-18: Cytokinetics To Present Additional Results From COSMIC-HF At American College of Cardiology's 68th Annual Scientific Session

Financial news for CYTK dated on 2019-03-11: Cytokinetics To Present Additional Results From COSMIC-HF At American College of Cardiology's 68th Annual Scientific Session

Financial news for CYTK dated on 2019-03-07: Cytokinetics Highlights Presentation Of Results From FORTITUDE-ALS At American Academy Of Neurology 71st Annual Meeting

Financial news for CYTK dated on 2019-03-07: Cytokinetics Entered Sales Agreement Through Which Co May Offer, Sell Common Stock Of Up to \$35M Through Cantor Fitzgerald

Financial news for CYTK dated on 2019-02-21: Cytokinetics Q4 EPS \$(0.48) Beats \$(0.52) Estimate, Sales \$9.377M Beat \$3.94M Estimate

Financial news for CYTK dated on 2019-02-21: Amgen, Cytokinetics Report METEORIC-HF Second Phase 3 Trial Of Omecamtiv Mecarbil Is Open For Enrollment

Financial news for CYTK dated on 2019-02-21: The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan

Financial news for CYTK dated on 2019-02-20: Cytokinetics Announces Initiation Of Phase 1 Clinical Study Of AMG 594, A Cardiac Troponin Activator

Financial news for CYTK dated on 2019-01-22: Cytokinetics Says it is Preparing to Conduct an Additional Phase 1 Study of Reldesemtiv

Financial news for CYTK dated on 2018-12-05: Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor

Financial news for CYTK dated on 2018-12-03: Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More

Financial news for CYTK dated on 2018-11-27: Cytokinetics Completes Enrollment In FORTITUDE-ALS, Phase 2 Clinical Trial Of Reldesemtiv In Patients With ALS; Clinical

## Trial Results Expected In First Half Of 2019

Financial news for CYTK dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for CYTK dated on 2018-11-01: Cytokinetics Q3 EPS \$(0.40) Beats \$(0.51) Estimate, Sales \$10.64M Beat \$3.15M Estimate

Financial news for CYTK dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for CYTK dated on 2018-10-17: 48 Biggest Movers From Yesterday

Financial news for CYTK dated on 2018-10-16: Cytokinetics Unveils Expanded Development Pipeline And Provides Key Updates On Late-Stage Clinical Research Programs At R&D Day

Financial news for CYTK dated on 2018-10-08: The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

Financial news for CYTK dated on 2018-10-05: Cytokinetics, Astellas Offer Update Related To Collaborative Skeletal Muscle Program

Financial news for CYTK dated on 2018-09-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CYTK dated on 2018-09-21: Cantor Fitzgerald's 7 Buys For 7 Biotechs

Financial news for CYTK dated on 2018-09-21: Cantor Fitzgerald Initiates Coverage On Cytokinetics with Overweight Rating, Announces \$14 Price Target

Financial news for CYTK dated on 2018-09-16: The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for CYTK dated on 2018-09-10: Morgan Stanley Assumes Cytokinetics at Equal-Weight, Announces Price Target \$10

Financial news for CYTK dated on 2018-08-02: Stocks Which Set New 52-Week Low Yesterday, August 1st

Financial news for CYTK dated on 2018-08-01: 10 Biggest Price Target Changes For Wednesday

Financial news for CYTK dated on 2018-08-01: Cytokinetics Downgraded On Data Delay

Financial news for CYTK dated on 2018-08-01: Benzinga's Top Upgrades, Downgrades For August 1, 2018

Financial news for CYTK dated on 2018-08-01: Morgan Stanley Downgrades Cytokinetics to Equal-Weight, Lowers Price Target to \$9

Financial news for CYTK dated on 2018-07-26: Cytokinetics Q2 EPS \$(0.51), Inline, Sales \$6.2M Beat \$5.19M Estimate

Financial news for CYTK dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for CYTK dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for CYTK dated on 2018-06-19: 60 Biggest Movers From Yesterday

Financial news for CYTK dated on 2018-06-18: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher

Financial news for CYTK dated on 2018-06-18: '\$CYTK -15% on some really mediocre SMA data presented over the weekend. Squint hard and you might see some benefit in ambulatory Type III patients but the bar is so much higher these days.'-STAT's Adam Feuerstein Tweets

Financial news for CYTK dated on 2018-06-18: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for CYTK dated on 2018-06-18: Mid-Day Market Update: Verastem Shares Climb On Duvelisib Data; ZIOPHARM Oncology Shares Slide

Financial news for CYTK dated on 2018-06-18: Mid-Morning Market Update: Markets Open Lower; Vintage Capital To Acquire Rent-A-Center For \$15/Share

Financial news for CYTK dated on 2018-06-16: Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at 2018 Annual Cure SMA Conference

Financial news for CYTK dated on 2018-06-08: Cytokinetics Announces Data From Phase 2 Clinical Study Of Reldesemtiv In Patients With Spinal Muscular Atrophy Will Be Presented At 2018 Annual Cure SMA Conference On June 16, 2018

Financial news for CYTK dated on 2018-05-17: Cytokinetics, Cure SMA Report Renewal, Expanded Partnership To Advance Education, Awareness Of SMA

Financial news for CYTK dated on 2018-04-27: Benzinga's Daily Biotech Pulse: Intracellular Moves On Poster Presentation, Earnings Beats From Vertex, Exact Sciences

Financial news for CYTK dated on 2018-04-26: Cytokinetics Q1 EPS \$(0.56) Misses \$(0.51) Est., Sales \$5.27M Misses \$6.58M Est.

Financial news for CYTK dated on 2018-04-24: Cytokinetics On Phase 2 Study Of Reldesemtiv In Patients With Spinal Muscular Atrophy: Enrollment Stopped Short Of Targeted 72 Patients After Blinded Analyses Of Variability Showed Study Has Sufficient Statistical Power To Detect Relevant Differences

Financial news for CYTK dated on 2018-02-15: Cytokinetics Reports Q4 EPS \$(0.75) vs \$(0.70) Est., Sales \$6.2M vs \$6.3M Est.

Financial news for CYTK dated on 2018-02-15: Cytokinetics Earnings Outlook

Financial news for CYTK dated on 2017-12-11: A Peek Into The Markets: U.S. Stock Futures Signal Higher Start On Wall Street

Financial news for CYTK dated on 2017-12-11: 5 Stocks To Watch For December 11, 2017

Financial news for CYTK dated on 2017-12-08: Cytokinetics Reports VITALITY-ALS Did Not Meet Primary, Secondary Endpoints In Phase 3 Trial Of Tirasemtiv

Financial news for CYTK dated on 2017-11-30: New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability, Amplification of Skeletal Muscle Response to Nerve Activation

Financial news for CYTK dated on 2017-11-30: 36 Biggest Movers From Yesterday

Financial news for CYTK dated on 2017-11-29: 33 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CYTK dated on 2017-11-29: 35 Stocks Moving In Wednesday's Pre-Market Session

Financial news for CYTK dated on 2017-11-24: Seeing Notable Block Trade In Cytokinetics of 1.3M Shares At \$8/Share

Financial news for CYTK dated on 2017-11-22: Benzinga's Top Upgrades, Downgrades For November 22, 2017

Financial news for CYTK dated on 2017-11-22: Cantor Fitzgerald Downgrades Cytokinetics to Neutral

Financial news for CYTK dated on 2017-11-22: 40 Biggest Movers From Yesterday

Financial news for CYTK dated on 2017-11-21: Mid-Afternoon Market Update: Dow Gains 180 Points; DSW Shares Drop On Earnings Miss

Financial news for CYTK dated on 2017-11-21: Hearing Needham Downgrades Cytokinetics From Strong Buy to Buy

Financial news for CYTK dated on 2017-11-21: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CYTK dated on 2017-11-21: Mid-Day Market Update: Signet Jewelers Falls After Q3 Results; Cheetah Mobile Shares Surge

Financial news for CYTK dated on 2017-11-21: Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Expectations

Financial news for CYTK dated on 2017-11-21: Why Is Cytokinetics Plunging Today?

Financial news for CYTK dated on 2017-11-21: 33 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CYTK dated on 2017-11-21: Cytokinetics Shares To Resume Trade At 8 a.m. EST

Financial news for CYTK dated on 2017-11-21: Cytokinetics Reports Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints

Financial news for CYTK dated on 2017-11-21: Cytokinetics Halted, News Pending

Financial news for CYTK dated on 2017-10-26: Cytokinetics Q3 EPS \$(0.60) vs \$(0.62) Est., Sales \$6.18M vs \$6.47M Est.

Financial news for CYTK dated on 2017-10-06: Seaport Global Initiates Coverage On Cytokinetics with Buy Rating, Announces \$24.00 Price Target

Financial news for CYTK dated on 2017-09-19: UPDATE: Cytokinetics Says Coincident With Patient Dosing In Galactic-HF, Amgen Will Make \$10M Milestone Payment to Cytokinetics

Financial news for CYTK dated on 2017-09-19: Cytokinetics Reports Dosing of Initial Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure

Financial news for CYTK dated on 2017-08-07: Secondary Offering Lockups To Expire Today Include: Aeglea BioTherapeutics, Exact Sciences, Evolent Health, and Cytokinetics

Financial news for CYTK dated on 2017-08-02: Cytokinetics Reports Q2 EPS \$(0.60) vs \$(0.57) Est., Sales \$3.1M vs \$8.22M Est.

Financial news for CYTK dated on 2017-08-02: Cytokinetics Reports Results From Phase 2 Trial Of Omecamtiv Mecarbil In Japanese Patients With Heart Failure; Co. Eligible To Earn \$10M Milestone Payment From Amgen Upon First Patient Dosing In Phase 3 Trial

Financial news for CYTK dated on 2017-07-27: Cytokinetics Announces Start of Phase 2 Clinical Trial FORTITUDE-ALS

Financial news for CYTK dated on 2017-07-05: Cytokinetics Reports Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA

Financial news for CYTK dated on 2017-06-29: Cytokinetics Reports Initiation of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility

Financial news for CYTK dated on 2017-05-15: Cytokinetics Announces Orphan Drug Designation for CK-2127107

Financial news for CYTK dated on 2017-05-12: Cytokinetics Granted FDA Orphan Status for Fast Skeletal Muscle Troponin Activator

Financial news for CYTK dated on 2017-05-09: 20 Biggest Mid-Day Losers For Tuesday

Financial news for CYTK dated on 2017-05-09: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CYTK dated on 2017-05-09: Cytokinetics Prices 5.26M Share Offering @\$14.25/Share

Financial news for CYTK dated on 2017-05-08: Cytokinetics Reports Offering of \$75M in Shares

Financial news for CYTK dated on 2017-04-27: Cytokinetics Reports Q1 EPS \$(0.62) vs \$(0.27) Est., Sales \$4.2M

Financial news for CYTK dated on 2017-04-21: Cytokinetics Added to S&P SmallCap 600

Financial news for CYTK dated on 2017-04-18: 12 Biggest Mid-Day Gainers For Tuesday

Financial news for CYTK dated on 2017-04-18: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CYTK dated on 2017-03-29: Cytokinetics Reports Starts of Second Cohort in Phase 2 Trial of CK-2127107 in Patients with Spinal Muscular Atrophy

Financial news for CYTK dated on 2017-03-23: Cytokinetics Still A Buy After Phase 2 SMA Data

Financial news for CYTK dated on 2017-03-15: Traders Circulating New Bullish Report on Cytokinetics from SmithOnStocks: 'Cytokinetics: A Look at the Clinical Trial Programs Underway (CYTK, Buy, \$13.00)'

Financial news for CYTK dated on 2017-03-08: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for CYTK dated on 2017-03-08: Benzinga's Top Upgrades, Downgrades For March 8, 2017

Financial news for CYTK dated on 2017-03-08: Rodman & Renshaw Initiates Coverage On Cytokinetics With Buy, Announces \$25 Price Target

Financial news for CYTK dated on 2017-03-06: Cytokinetics Announces Add'l Results From COSMIC-HF Phase 2 Trial To Be Presented At Annual Scientific Session Mar. 18

Financial news for CYTK dated on 2017-02-16: Cytokinetics Reports Q4 Net Income \$0.18 Does Not Compare To \$(0.27), Rev. \$33.1M Does Not Compare To \$16.33M Est.

Financial news for CYTK dated on 2017-02-06: Benzinga's Top Upgrades, Downgrades For February 6, 2017

Financial news for CYTK dated on 2017-02-06: Needham Upgrades Cytokinetics To Strong Buy

Financial news for CYTK dated on 2017-02-02: Cytokinetics, Royalty Pharma Announce \$100 Million Transaction for Omecamtiv Mecarbil; Royalty Buys 4.5% Royalty On Worldwide Sales For \$90M, Plus \$10M Equity In Cytokinetics

Financial news for CYTK dated on 2016-12-27: 6 Stocks Analysts Forecast The Largest Year-Over-Year Revenue Declines

Financial news for CYTK dated on 2016-12-16: Cytokinetics Pops to High of \$12.15 on Volume Following CNBC Mention

Financial news for CYTK dated on 2016-12-09: Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND

Financial news for CYTK dated on 2016-12-07: Origent Data Sciences and Cytokinetics Present Analyses Demonstrating Baseline Data Predict Measures of Vital Capacity in Patients With ALS

Financial news for CYTK dated on 2016-12-01: Cytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil; Earns \$26.7M Milestone Payment From Amgen

Financial news for CYTK dated on 2016-10-28: 20 Biggest Mid-Day Gainers For Friday

Financial news for CYTK dated on 2016-10-27: Cytokinetics Reports Q3 EPS \$0.80 Does Not Compare To \$(0.29), Rev. \$59M

Financial news for CYTK dated on 2016-10-18: Cytokinetics Reports First Patient Has Been Enrolled in VIGOR-ALS

Financial news for CYTK dated on 2016-09-29: Cytokinetics Reports Early Termination of HSR Waiting Period for Expanded Collaboration with Astellas; Upfront Payment of \$65M from Astellas Due, Payable Within 30 Days

Financial news for CYTK dated on 2016-09-08: Cytokinetics Reports Triggering of Milestone Payment from Astellas Related to Next-Gen Fast Skeletal Muscle Activator Entering IND-Enabling Studies

Financial news for CYTK dated on 2016-09-01: 12 Biggest Mid-Day Losers For Thursday

Financial news for CYTK dated on 2016-09-01: Cytokinetics, Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development

Financial news for CYTK dated on 2016-07-28: Cytokinetics Reports Q2 EPS (0.29) vs. Est. \$(0.31), Rev. \$5.8M vs. Est. \$10.15M

Financial news for CYTK dated on 2016-07-27: Needham Maintains Buy on Cytokinetics, Raises PT to \$17.00, Says Amgen Decision to Move Omecamtiv to Phase III May Be An Upcoming Driver Of Upside

Financial news for CYTK dated on 2016-07-27: Cytokinetics And Astellas Announce Option Right For Tirasemtiv And Expansion Of Global Collaboration For CK-2127107 In ALS

Financial news for CYTK dated on 2016-06-30: Cytokinetics Reports Start of Phase 2 Clinical Trial of CK-2127107 in Patients With Chronic Obstructive Pulmonary Disease

Financial news for CYTK dated on 2016-04-28: Cytokinetics Reports Q1 EPS \$(0.31) vs. Est. \$(0.34), Rev. \$8.4M vs. Est. \$7.38M



Financial news for CYTK dated on 2016-04-04: Cytokinetics Reports Commencement of Phase 2 Trial of Omecamtiv Mecarbil in Japanese Subjects with Heart Failure

Financial news for CYTK dated on 2016-02-18: Why Does The Street Like Small-Caps Cytokinetics And Anavex?

Financial news for CYTK dated on 2016-02-16: Cytokinetics Sees FY16 Cash Sales \$13M-\$16M

Financial news for CYTK dated on 2016-02-16: Cytokinetics Reports Q4 EPS \$(0.24) vs \$(0.32) Est., Sales \$9.8M vs \$10.5M Est.

Financial news for CYTK dated on 2016-01-10: Cytokinetics Presents Exploratory Analyses of Data from Phase 3 Clinical Trial of Dexpramipexole in Patients with ALS

Financial news for CYTK dated on 2016-01-04: Roth Capital Positive On Cytokinetics, Says Patnerships And Regulatory Visibility Generates Compelling Investment Opportunity

Financial news for CYTK dated on 2016-01-04: Cytokinetics Reports Initiation of Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy

Financial news for CYTK dated on 2015-12-08: Cytokinetics Shares Up 6.5% On The Morning; Earlier News Of Cure SMA, Cytokinetics Collaboration To Increase Funding & Awareness For Spinal Muscular Atrophy

Financial news for CYTK dated on 2015-12-03: Cytokinetic Shares Falling

Financial news for CYTK dated on 2015-11-08: Amgen, Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015

Financial news for CYTK dated on 2015-11-02: Mid-Afternoon Market Update: Dow Surges 150 Points; Lendingtree Shares Slide

Financial news for CYTK dated on 2015-11-02: Mid-Day Market Update: Dyax Jumps On Acquisition News; Endurance International Shares Dip

Financial news for CYTK dated on 2015-10-29: Cytokinetics Sees FY15 Rev. \$44-\$47M vs. Est. \$32.98M

Financial news for CYTK dated on 2015-10-29: Cytokinetics Reports Q3 EPS \$(0.23) vs. Est. \$(0.30), Rev. \$7.9M vs. Est. \$11.24M

Financial news for CYTK dated on 2015-10-27: Amgen and Cytokinetics Announce Positive Top-Line Results From COSMIC-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Financial news for CYTK dated on 2015-10-19: 8-K from Cytokinetics Shows Entered Loan, Security Deal with Oxford Finance, Silicon Valley Bank for \$40M in Series of Term Loans, \$15M Borrowing from Lenders

Financial news for CYTK dated on 2015-07-29: Cytokinetics Reports Q2 Loss of \$0.27/Share vs Loss of \$0.24/Share Est., Sales \$6.5M vs \$7M Est.; Sees Sales \$44M-\$47M

Financial news for CYTK dated on 2015-07-15: Cowen & Company Initiates Coverage on Cytokinetics at Outperform, Announces \$9.00 PT

Financial news for CYTK dated on 2015-07-14: Mid-Day Market Update: Vince Holding Declines After CEO Resignation; Natural Health Trends Shares Surge

Financial news for CYTK dated on 2015-07-14: Mid-Morning Market Update: Markets Rise; JPMorgan Earnings Beat Views

Financial news for CYTK dated on 2015-07-14: Cytokinetics Reports Initiating Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS

Financial news for CYTK dated on 2015-07-14: Cytokinetics, ALS Association Announce Awarding of Grant for Phase 3 Clinical Trial and Biomarker Research Partnership

Financial news for CYTK dated on 2015-06-19: Cytokinetics Shows Results Of Phase I Studies of CK-2127107

Financial news for CYTK dated on 2015-05-08: Cytokinetics Director Gage Buys 10,000 Shares @\$5.71/Share -Form 4

Financial news for CYTK dated on 2015-02-26: Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart Failure

Financial news for CYTK dated on 2015-02-13: Morning Market Gainers

Financial news for CYTK dated on 2015-02-13: Piper Jaffray Upgrades Cytokinetics to Overweight

Financial news for CYTK dated on 2015-01-12: FDA Approves Cytori U.S. Pivotal Scleroderma Trial

Financial news for CYTK dated on 2014-12-31: Mid-Afternoon Market Update: U.S. Stocks Turn Red; Tekmira Pharmaceuticals Shares Climb Following Clinical Study Update

Financial news for CYTK dated on 2014-12-31: Mid-Day Gainers From New Year's Eve 2014: NephroGenex And Other Biopharma Stocks

Financial news for CYTK dated on 2014-12-31: Mid-Day Market Update: Meadowbrook Insurance Shares Jump On Acquisition News; Crude Oil Drops Over 2%

Financial news for CYTK dated on 2014-12-31: Cytokinetics Surges Amid Roth Capital Raising Its Price Target

Financial news for CYTK dated on 2014-12-31: Cytokinetics Shares Rise 13% Following Roth Capital Raising PT from \$13 to \$18

Financial news for CYTK dated on 2014-12-31: Biotech Stocks Make Big Moves In Final Days Of 2014

Financial news for CYTK dated on 2014-12-29: 13G Filing from Astellas Pharma on Cytokinetics Shows 5.28% Stake

Financial news for CYTK dated on 2014-12-23: 3 Stocks Blowing Up On Social Media

Financial news for CYTK dated on 2014-12-23: Morning Market Movers

Financial news for CYTK dated on 2014-12-23: Tuesday's #PreMarket Movers: NQ Mobile, Cytokinetics, Walgreen And More

Financial news for CYTK dated on 2014-12-23: UPDATE: Cytokinetics In Common Stock Purchase Deal with Astellas for ~2.04M Shares at \$4.90/Share

Financial news for CYTK dated on 2014-12-23: UPDATE: Cytokinetics Will Receive Upfront Payment \$30M, Could Get Milestone Payments for Up to \$15M

Financial news for CYTK dated on 2014-12-23: Shares of Cytokinetics to Resume Trade at 8 a.m. EDT

Financial news for CYTK dated on 2014-12-23: Cytokinetics, Astellas Announces Expansion of Deal for Development of CK-2127107 in Spinal Muscular Atrophy, Other Neuromuscular Indications

Financial news for CYTK dated on 2014-12-23: Shares of Cytokinetics Halted News Pending

Financial news for CYTK dated on 2014-10-27: Cytokinetics Offers Development Program Update for Omecamtiv Mecarbil: Saw No Clinically Meaningful Differences Between Two Groups

Financial news for CYTK dated on 2014-10-20: Cytokinetics Offers Update on Development Program for Tirasemtiv

Financial news for CYTK dated on 2014-10-13: Cytokinetics Provides Update for CK-2127107

Financial news for CYTK dated on 2014-09-10: Lands' End Jumps On Strong Quarterly Earnings; GT Advanced Technologies Shares Slide

Financial news for CYTK dated on 2014-09-04: Markets Open Higher; VeriFone Profit Tops Street View

Financial news for CYTK dated on 2014-09-02: MLV & Co. Sees Good Things Ahead For Cytokinetics

Financial news for CYTK dated on 2014-07-10: Lansdowne Increases Stake in Cytokinetics From 6.34% to 7.7%

Financial news for CYTK dated on 2014-07-10: Cytokinetics Reports Added Results Related to Tirasemtiv from Pre-Specified Subgroup Analyses of BENEFIT-ALS

Financial news for CYTK dated on 2014-06-02: Cytokinetics Announces Further Results

from BENEFIT-ALS

Financial news for CYTK dated on 2014-06-02: Cytokinetics Offers Further Results from BENEFIT-ALS Related to Effects Following Withdrawal of Tirasemtiv

Financial news for CYTK dated on 2014-06-02: Cytokinetics Offers Further Results from BENEFIT-ALS Related to Effects Following Withdrawal of Tirasemtiv

Financial news for CYTK dated on 2014-05-27: Cytokinetics Reports Additional BENEFIT-ALS Data to be Presented at Joint Congress of European Neurology

Financial news for CYTK dated on 2014-05-06: Cytokinetics, Incorporated Reports Q1 EPS of \$(0.27) vs \$(0.34) Est; Revenue of \$8.0M vs \$7.69M Est

Financial news for CYTK dated on 2014-04-25: MLV & Co. Downgrades Cytokinetics, Incorporated to Hold, Lowers PT to \$5.00

Financial news for CYTK dated on 2014-04-25: Piper Jaffray Downgrades Cytokinetics, Incorporated to Neutral, Lowers PT to \$7.00

Financial news for CYTK dated on 2014-04-25: Stocks Hitting 52-Week Lows

Financial news for CYTK dated on 2014-04-25: Cytokinetics Shares Fall 68% on Failed BENEFIT-ALS Trial Result

Financial news for CYTK dated on 2014-04-25: PREVIEW: CYTOKINETICS to Resume Trading at 8:00 AM ET

Financial news for CYTK dated on 2014-04-25: UPDATE: Cytokinetics Reports Top-Line Results from BENEFIT-ALS Showed Did Not Reach Primary Efficacy Endpoint, Mixed Effects on Secondary Endpoints

Financial news for CYTK dated on 2014-04-25: Cytokinetics Reports Top-Line Results from BENEFIT-ALS Showed Did Not Reach Primary Efficacy Endpoint, Mixed Effects on Secondary Endpoints

Financial news for CYTK dated on 2014-04-25: Cytokinetics Shares Halted News Pending

Financial news for CYTK dated on 2014-04-21: Cytokinetics Move Higher; May be Attributed to Positive Newsletter Mention

Financial news for CYTK dated on 2014-04-09: Mid-Afternoon Market Update: Markets Post a Large Rally as Intuitive Surgical Shares Remain Down

Financial news for CYTK dated on 2014-04-09: Mid-Day Market Update: Alcoa Surges On Upbeat Earnings; Intuitive Surgical Shares Slip

Financial news for CYTK dated on 2014-04-07: 13G Filing from SAC Capital on Cytokinetics Shows 5.5% Stake

Financial news for CYTK dated on 2014-03-28: Cytokinetics Reports Opening of Enrollment for Expansion of COSMIC-HF

Financial news for CYTK dated on 2014-03-27: Cytokinetics Begins Multi-Dose Phase I Clinical Trial of CK-2127107

Financial news for CYTK dated on 2014-03-05: Roth Capital Reiterates Buy on Cytokinetics, Incorporated, Announces \$25.00 PT

Financial news for CYTK dated on 2014-02-20: Cytokinetics Prices \$35M in Shares at \$8/Share

Financial news for CYTK dated on 2014-02-13: This Week's Sector Gainers And Losers

Financial news for CYTK dated on 2014-02-06: Cytokinetics Expecting Added CK-2127107 Phase I Studies This Year

Financial news for CYTK dated on 2014-02-06: Cytokinetics, Incorporated Reports Q4 EPS of \$0.21 vs \$(0.08) Est; Revenue of \$24.30M vs \$19.14M Est

Financial news for CYTK dated on 2014-01-13: Cytokinetics Offers Update on Program for Omecamtiv Mercarbil, Says Size of Expansion Phase Boosted

Financial news for CYTK dated on 2013-12-10: Cytokinetics Issues Results from First-Time-In-Humans Trial, Says CK-2127107 Appears Well Tolerated

Financial news for CYTK dated on 2013-12-08: Cytokinetics Presents Update on BENEFIT-ALS at International Symposium on ALS/MND

Financial news for CYTK dated on 2013-11-06: Cytokinetics Files \$150M Mixed Securities Shelf

Financial news for CYTK dated on 2013-10-30: Cytokinetics, Incorporated Sees FY2013 Sales \$40.0M-42.0M vs \$30.80M Est

Financial news for CYTK dated on 2013-10-30: Cytokinetics, Incorporated Reports Q3 EPS of \$(0.43) vs \$(0.10) Est; Revenue of \$12.60M vs \$16.96M Est

Financial news for CYTK dated on 2013-10-11: Cytokinetics Shares Holding Over \$6.75 Level, Up 8+% Today; Needham Earlier Suggested Market Misread Co./Amgen's Data on Omecamtiv, Called Results 'More Than Positive Enough'

Financial news for CYTK dated on 2013-09-23: Cytokinetics Reports Added Safety, Pharmacodynamic Results from ATOMIC-AHF Study

Financial news for CYTK dated on 2013-09-03: Hearing Leerink Defending Cytokinetics

Financial news for CYTK dated on 2013-09-03: Morning Market Losers

Financial news for CYTK dated on 2013-09-03: Leerink Swann's Schwartz Believes Cytokinetics, Amgen Data Could Warrant More Phase III Testing

Financial news for CYTK dated on 2013-09-03: Benzinga's Top Pre-Market Losers

Financial news for CYTK dated on 2013-09-03: Cytokinetics Shares Fall 33% in Pre-Market on Failed Phase 2 ATOMIC-AHF Study

Financial news for CYTK dated on 2013-09-03: Amgen, Cytokinetics Announce Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil Did Not Meet Primary Endpoint

Financial news for CYTK dated on 2013-07-31: Cytokinetics, Incorporated Reports Q2 EPS of \$(0.58) vs \$(0.54) Est; Revenue of \$1.0M vs \$3.20M Est

Financial news for CYTK dated on 2013-07-23: Leerink Swann's Schwartz Believes Update on Cytokinetics ALS Trial Removes Overhang, Reiterates Outperform

Financial news for CYTK dated on 2013-07-23: Cytokinetics Shares to Resume Trade at 8AM EDT

Financial news for CYTK dated on 2013-07-23: Cytokinetics Offers Update, Revised Guidance for BENEFIT-ALS, Sees Patient Enrollment Concluded in 2013, Results in Early 2014

Financial news for CYTK dated on 2013-07-23: Cytokinetics Halted with News Pending

Financial news for CYTK dated on 2013-07-17: Leerink Swann Initiates Coverage on Cytokinetics, Incorporated at Outperform, Announces \$20.00 PT

Financial news for CYTK dated on 2013-07-08: Morning Market Losers

Financial news for CYTK dated on 2013-07-08: Cytokinetics Resumes Trading Down 5%

Financial news for CYTK dated on 2013-07-08: Cytokinetics Shares to Resume Trade at 8AM EDT

Financial news for CYTK dated on 2013-07-08: UPDATE: Cytokinetics Reports Programming Error in Data Capture, Says No Placebo Patients Got Incorrect Treatment, DSMB Reported No Concerns on Patient Safety

Financial news for CYTK dated on 2013-07-08: UPDATE: Cytokinetics Halted News Disseminated: Issues Update on BENEFIT-ALS, Says 58 Patients Received Placebo Instead of Drug

Financial news for CYTK dated on 2013-07-08: Cytokinetics Halted News Disseminated: Issues Update on BENEFIT-ALS

Financial news for CYTK dated on 2013-06-26: Canaccord Genuity Reiterates Buy on Cytokinetics on CK357 Potential

Financial news for CYTK dated on 2013-06-25: Mid-Morning Market Update: Markets Open Higher, Walgreen Profit Misses Estimates

Financial news for CYTK dated on 2013-06-18: 13D Filing from Amgen on Cytokinetics Shows Raised 7.58% Stake, Had Shown 2.34% as of Feb. 29th, 2012

Financial news for CYTK dated on 2013-06-18: Market Wrap for Tuesday, June 18: Stocks Rally Ahead of Fed Statement

Financial news for CYTK dated on 2013-06-18: Afternoon Market Gainers

Financial news for CYTK dated on 2013-06-18: Cytokinetics Announces Results From ATOMIC-AHF Will Be Presented At Late Breaking Clinical Trials Session At The European Society Of Cardiology Congress 2013

Financial news for CYTK dated on 2013-06-12: Afternoon Market Gainers

Financial news for CYTK dated on 2013-06-12: Cytokinetics Shares Resume Trade, Now Up 18%

Financial news for CYTK dated on 2013-06-12: Shares of Cytokinetics to Resume Trade at 8AM EDT

Financial news for CYTK dated on 2013-06-12: UPDATE: Cytokinetics Will Receive \$25 Million Plus Potential Milestone Payments and Royalties

Financial news for CYTK dated on 2013-06-12: Amgen, Cytokinetics Announce Expansion of License for Omecamtiv Mecarbil, Will Receive \$25M Plus Potential Milestone, Cytokinetics Will Also Get Possible Royalties

Financial news for CYTK dated on 2013-06-12: Cytokinetics Halted News Pending

Financial news for CYTK dated on 2013-04-30: Cytokinetics, Incorporated Reports Q1 EPS of \$(0.09), Inline; Revenue of \$821.0K vs \$680.0K Est

Financial news for CYTK dated on 2013-01-04: UPDATE: Piper Jaffray Initiates Coverage on Cytokinetics with Overweight Rating, \$4 PT

Financial news for CYTK dated on 2013-01-04: Piper Jaffray Initiates Coverage on Cytokinetics, Incorporated at Overweight, Announces \$4.00 PT

Financial news for CYTK dated on 2012-12-18: Cytokinetics to Transfer Listing from NASDAQ Global Market to NASDAQ Capital Market

Financial news for CYTK dated on 2012-11-29: Cytokinetics Opens Third and Final Cohort in ATOMIC-AHF

Financial news for CYTK dated on 2012-11-27: UPDATE: Dawson James Initiates Cytokinetics at Market Outperform on Competitive Positioning

Financial news for CYTK dated on 2012-11-27: Dawson James Initiates Coverage Cytokinetics at Market Outperform, Announces PT of \$2.00

Financial news for CYTK dated on 2012-11-26: Cytokinetics Offers Results from Phase IIA Trial of Tirasemtiv for Myasthenia Gravis

Financial news for CYTK dated on 2012-11-14: Cytokinetics Spikes Higher; Traders Attributing to Positive Article

Financial news for CYTK dated on 2012-11-14: Cytokinetics Moves Higher on Article Regarding ALS Treatment

Financial news for CYTK dated on 2012-10-30: Cytokinetics Reports Q3 EPS \$-0.07 vs \$-0.11 Est; Revenues \$1.7M vs \$1.25M Est

Financial news for CYTK dated on 2012-08-01: Benzinga's Top Initiations

Financial news for CYTK dated on 2012-07-31: UPDATE: Rodman & Renshaw Maintains Outperform on Cytokinetics; \$2 PT

Financial news for CYTK dated on 2012-07-26: Cytokinetics Announces Heart Failure Program Update

Financial news for CYTK dated on 2012-07-02: Benzinga's Top Initiations

Financial news for CYTK dated on 2012-06-20: Cytokinetics, Incorporated Announces \$60 Million Financing

Financial news for CYTK dated on 2012-06-19: Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants

Financial news for CYTK dated on 2012-06-19: Cytokinetics Receives NASDAQ Notice of Minimum Bid Price Non-Compliance

Financial news for CYTK dated on 2012-05-24: Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients With Acute Heart Failure

Financial news for CYTK dated on 2012-04-25: Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2012-04-19: Cytokinetics Announces CK-2017357 Receives Fast Track Designation From the FDA for the Potential Treatment of Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2012-04-12: UPDATE: MLV Initiates Cytokinetics with Buy, \$4 PT

Financial news for CYTK dated on 2012-03-07: Cytokinetics Announces Changes to Its Board of Directors

Financial news for CYTK dated on 2012-03-06: Cytokinetics Announces That the European Medicines Agency Has Granted CK-2017357 Orphan Medicinal Product Designation for the Treatment of Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2012-02-21: Cytokinetics Announces Initiation of Phase I Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Healthy Volunteers

Financial news for CYTK dated on 2011-11-30: Cytokinetics Announces Positive Results From Phase II Clinical

Financial news for CYTK dated on 2011-11-29: Cytokinetics Announces Opening of Third Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2011-11-22: Cytokinetics to Present Clinical Trial Data Relating to CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2011-11-01: Rodman & Renshaw Reiterates Cytokinetics Market Outperform, \$4 PT

Financial news for CYTK dated on 2011-11-01: Cytokinetics Announces Initiation of Second Cohort of Ongoing Phase II Clinical Trial Evaluating CK-2017357 in Patients With ALS

Financial news for CYTK dated on 2011-10-19: Rodman & Renshaw Maintains Outperform Rating and \$4 PT on Cytokinetics

Financial news for CYTK dated on 2011-10-18: Cytokinetics Announces Strategic Restructuring; Cuts 18 Jobs

Financial news for CYTK dated on 2011-10-13: UPDATE: Rodman & Renshaw Initiates Coverage on Cytokinetics at Market Outperform

Financial news for CYTK dated on 2011-10-13: Rodman & Renshaw Initiates Cytokinetics at Market Outperform, \$4 PT

Financial news for CYTK dated on 2011-09-27: Cytokinetics Announces First Publication on Smooth Muscle Myosin Inhibitors

Financial news for CYTK dated on 2011-08-19: Cytokinetics Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet

Financial news for CYTK dated on 2011-06-21: Cytokinetics Announces Opening of Next Phase II Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis

Financial news for CYTK dated on 2011-06-02: Cytokinetics Announces Successful Completion of Phase IIA "Evidence of Effect" Clinical Trial of CK-2017357

Financial news for CYTK dated on 2011-04-19: Cytokinetics Announces Opening of Phase IIb Clinical Trial of Intravenous Formulation of Omecamtiv Mecarbil in Patients With Acute Heart Failure

Financial news for CYTK dated on 2011-04-18: Cytokinetics Announces \$20 Million Financing

Financial news for CYTK dated on 2011-04-18: Cytokinetics Announces Presentation of Data From a Phase IIa Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis at the 63rd Annual Meeting of the American Academy of Neurology (CYTK)

Financial news for CYTK dated on 2011-04-12: Cytokinetics Up 9% (CYTK)

Financial news for CYTK dated on 2011-04-11: Top Trade Ideas for Tuesday, April 12

Financial news for CYTK dated on 2011-04-11: Cytokinetics Announces Data From Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis to Be Presented at the 63rd Annual Meeting of the American Academy of Neurology

Financial news for CYTK dated on 2011-01-04: Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial

Financial news for CYTK dated on 2010-12-13: Afternoon Market Update (LCC, UAL, LFL, GOL, RY, CYTK)

Financial news for CYTK dated on 2010-12-08: Cytokinetics Setting Up Well Technically

Financial news for CYTK dated on 2010-05-11: How Best To Play The Relief Rally In The Stock Market

Financial news for CYTK dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for CYTK dated on 2010-03-10: Benzinga's Top Pre-Market Gainers (AEO, FACT, ITMN, CYTK)

Financial news for CYTK dated on 2009-12-10: Benzinga's Top Pre- Market Losers (CIEN, LLY, OSIP, PROV, CYTK, AOL, SIGA)

Financial news for CYTK dated on 2009-09-28: New 52-Week High (ACS, COMS, GMCR, CYTK, RINO)